Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386104971> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- W4386104971 abstract "Background Rheumatoid arthritis (RA) is an autoimmune disease that primarily affects the small joints of the hand, wrist, and feet. If left untreated, it can lead to extensive impacts on quality of life, with loss of productivity due to damaged and deformed joints. It is also associated with significant extra-articular manifestations and mortality. The cause of developing the disease is still unknown which leads to ongoing studies to further understand the pathogenesis and find new treatment targets and new classes of therapeutics. One of the studied markers is Galectin-1 (Gal-1). Gal-1 is a part of Galectin family and is their prototype. It could be found in a large number of tissues with pro-inflammatory and antiinflammatory effects depending on the cellular microenvironment. Objectives To evaluate the serum level of Galectin-1 in Egyptian rheumatoid arthritis patients and controls. Patient and methods This case-control study included 20 Egyptian patients with rheumatoid arthritis diagnosed according to 2010 ACREULAR criteria and 20 Egyptian healthy controls. Every patient is subjected to full clinical examination; swollen joints, tender joints, deformity, laboratory investigations; serum Galectin-1 level, ESR, CRP, CBC, SGPT, SGOT, creatinine, urea, Anti-CCP, RF. Results Comparing serum Galectin-1 levels between Egyptian RA cases and controls, there was a highly statistically significant increase in the serum Galectin-1 level in RA Cases group than the control group with a p-value <0.001 with a cut-off point between the control group and Cases group > 15 (ng/ml). There was a non-significant change in serum Galectin-1 level between different disease activity categories according to DAS28-ESR and DAS28-CRP. Conclusion Our study demonstrated the usefulness of measuring serum Galectin-1 in Egyptian patients with RA with high validity. This proves the role of Galectin-1 in RA pathogenesis." @default.
- W4386104971 created "2023-08-24" @default.
- W4386104971 creator A5027329349 @default.
- W4386104971 creator A5040630583 @default.
- W4386104971 creator A5066053985 @default.
- W4386104971 creator A5069940449 @default.
- W4386104971 date "2023-06-01" @default.
- W4386104971 modified "2023-09-27" @default.
- W4386104971 title "Serum Galectin-1 Level in Egyptian Patients with Rheumatoid Arthritis: A Pilot Study" @default.
- W4386104971 doi "https://doi.org/10.1093/qjmed/hcad069.684" @default.
- W4386104971 hasPublicationYear "2023" @default.
- W4386104971 type Work @default.
- W4386104971 citedByCount "0" @default.
- W4386104971 crossrefType "journal-article" @default.
- W4386104971 hasAuthorship W4386104971A5027329349 @default.
- W4386104971 hasAuthorship W4386104971A5040630583 @default.
- W4386104971 hasAuthorship W4386104971A5066053985 @default.
- W4386104971 hasAuthorship W4386104971A5069940449 @default.
- W4386104971 hasConcept C126322002 @default.
- W4386104971 hasConcept C156293190 @default.
- W4386104971 hasConcept C203014093 @default.
- W4386104971 hasConcept C2776336362 @default.
- W4386104971 hasConcept C2777077863 @default.
- W4386104971 hasConcept C2777575956 @default.
- W4386104971 hasConcept C2780306776 @default.
- W4386104971 hasConcept C2780942790 @default.
- W4386104971 hasConcept C71924100 @default.
- W4386104971 hasConcept C90924648 @default.
- W4386104971 hasConceptScore W4386104971C126322002 @default.
- W4386104971 hasConceptScore W4386104971C156293190 @default.
- W4386104971 hasConceptScore W4386104971C203014093 @default.
- W4386104971 hasConceptScore W4386104971C2776336362 @default.
- W4386104971 hasConceptScore W4386104971C2777077863 @default.
- W4386104971 hasConceptScore W4386104971C2777575956 @default.
- W4386104971 hasConceptScore W4386104971C2780306776 @default.
- W4386104971 hasConceptScore W4386104971C2780942790 @default.
- W4386104971 hasConceptScore W4386104971C71924100 @default.
- W4386104971 hasConceptScore W4386104971C90924648 @default.
- W4386104971 hasIssue "Supplement_1" @default.
- W4386104971 hasLocation W43861049711 @default.
- W4386104971 hasOpenAccess W4386104971 @default.
- W4386104971 hasPrimaryLocation W43861049711 @default.
- W4386104971 hasRelatedWork W2077699888 @default.
- W4386104971 hasRelatedWork W2086382866 @default.
- W4386104971 hasRelatedWork W2156283049 @default.
- W4386104971 hasRelatedWork W2316954211 @default.
- W4386104971 hasRelatedWork W2427075784 @default.
- W4386104971 hasRelatedWork W2761967325 @default.
- W4386104971 hasRelatedWork W2963886728 @default.
- W4386104971 hasRelatedWork W3030951269 @default.
- W4386104971 hasRelatedWork W4237221801 @default.
- W4386104971 hasRelatedWork W71700122 @default.
- W4386104971 hasVolume "116" @default.
- W4386104971 isParatext "false" @default.
- W4386104971 isRetracted "false" @default.
- W4386104971 workType "article" @default.